← Oncology Approval Tracker

FDA DECISION ·

Jaypirca

pirtobrutinib · Eli Lilly and Company

Traditional approvalTraditional conversionChronic lymphocytic leukemia and small lymphocytic lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory CLL or SLL previously treated with a covalent BTK inhibitor.

LAMPGEN ANALYSIS

Why it matters

Traditional approval also broadened the population from the 2023 accelerated label, which required prior BTK and BCL-2 inhibitor treatment.

What research teams should watch

Distinguish prior covalent and noncovalent BTK inhibitor exposure in screening and identify the specific reason prior therapy stopped.

PRIMARY RECORDS

Sources